Advaxis Stumbles Further As Amgen Exits Early-Stage Cancer Immunotherapy Pact
Executive Summary
Troubled by a clinical hold for another program, Advaxis now regains all rights to ADXS-NEO, a personalized immunotherapy in Phase I for cervical and head-and-neck cancers.
You may also be interested in...
Advaxis To Seek New Life In Merger With Ayala
The new company will focus mainly on Ayala’s lead candidate for desmoid tumors, but minority owner Advaxis will take over management.
Deal Watch: Gilead Signs Two Deals In Two Days To Increase R&D Emphasis
As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period…
Is Imfinzi The Culprit As Advaxis Combo Trial Goes On Hold After Death?
The FDA has placed a clinical hold on a Phase I/II trial for HPV-related cancers of Advaxis' axalimogene filolisbac in combination with Imfinzi after a patient died due to respiratory failure but analysts at Jefferies believe the fault could lie with AstraZeneca's PD-L1 inhibitor.